Table 2

Serum antibodies to JCV, BKV, and SV40 and their relation to the risk of a subsequent primary malignant brain tumor, Washington County, MD, 1975–2000

Polyomavirus antibodiesCasesControlsMatched OR95% CI
n(%)n(%)
JCVa
 <6408(18.2)22(25.0)1.00
 640 or 256022(50.0)41(46.6)1.44(0.57–3.64)
 ≥1024014(31.8)25(28.4)1.49(0.55–4.07)
 ≥64036(81.8)66(75.0)1.46(0.61–3.50)
BKVa
 <6408(18.2)12(13.6)1.00
 640 or 256017(38.6)39(44.3)0.61(0.19–1.94)
 ≥1024019(43.2)37(42.0)0.72(0.23–2.27)
 ≥64036(81.8)76(86.4)0.66(0.22–1.95)
SV40b
 Negative39(88.6)78(88.6)1.00
 Weak positivec1(2.3)4d(4.5)0.45(0.04–4.82)
 Positivec4(9.1)6(6.8)1.33(0.35–5.11)
 Positivee5(11.4)10d(11.4)1.00(0.30–3.32)
  • a Antibody titers measured by ELISA.

  • b Antibodies measured by plaque neutralization assay.

  • c Weak positive is defined as positive at 1:10 serum dilution and negative at 1:40 dilution; positive is defined as positive at both dilutions.

  • d Includes one specimen that was positive at the 1:10 dilution but could not be interpreted at the 1:40 dilution.

  • e This positive category includes both weak positives and positives.